CVS Health's Drugstore Breakup Doesn't Unlock a Discount: At $180.5 Billion, the Market Already Pays for Both Halves

CVS Health will break itself into two independent public companies, and the drugstore chain is the half investors get to value first. In a Form 8-K filed Nov. 4, 2026, the company said it will spin its roughly 9,000-store pharmacy business into a standalone public company called CVS Pharmacy, while Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health stay behind under the CVS Health name. David Joyner stays with the healthcare solutions company; Prem Shah, the current group president, becomes CEO of CVS Pharmacy.

The third quarter is why CVS is up 3.3% today, not the separation. Revenue rose 5.4% to $108.4 billion, adjusted operating income reached $4.19 billion, and adjusted EPS of $2.09 beat the roughly $1.63 consensus by about 27% against $1.60 a year earlier. Management then raised full-year adjusted EPS guidance to at least $8.20 from $7.90-$8.10 and lifted operating cash flow guidance to at least $15.5 billion from at least $11.5 billion.

The market's verdict so far is muted for a structural transformation. After The Wall Street Journal and The Financial Times reported the breakup late on Nov. 3, shares rose about 1.2% in extended trading; CVS Health closed at $91.41 on Nov. 4, up 3.3% from $88.51, alongside the earnings beat. That is the tell: the separation cannot be priced until the Form 10 publishes standalone financials, so the stock still trades on execution.

Two features of those numbers matter for the breakup. Health Services swung from a $3.9 billion GAAP operating loss in Q3 2025 to $1.98 billion of operating income this year, so the PBM half is recovering from 2025 charges rather than compounding a clean base. And Health Care Benefits operating income fell from $2.19 billion in Q2 2026 to $653 million in Q3, a reminder that the health-plan half earns in lumps.

The re-rating case rests on a simple claim: the parts are worth more than the whole. Run it on peer multiples and the gap mostly closes. Valuing the health half on Cigna's 0.37x sales and the chain on the 0.16x sales the private market paid for Walgreens puts the two companies at about $125 billion; push the health half to Elevance Health's 0.55x and the chain to McKesson's 0.30x and you reach about $194 billion. Today's $180.5 billion enterprise value already sits in the top third of that range, so the separation does not release a discount — it puts the valuation of a $142 billion pharmacy chain on the table for public inspection.

The nearest template for what CVS Health becomes is Cigna: a health plan bolted to a PBM, with no owned chain. Cigna trades at 8.2x trailing EBITDA, the cheapest multiple in the peer group, and at 8.9x forward earnings against CVS's 11.1x on its own guidance. That is not an accounting accident; it is the market's standing verdict on the payer-plus-PBM structure CVS Health will now be.

The chain has a harsher benchmark still. Sycamore Partners agreed in March 2025 to take Walgreens Boots Alliance private at up to $23.7 billion including debt and payouts — a company with $147.7 billion of fiscal 2024 sales and a $115.8 billion US retail pharmacy segment, or roughly 0.16x sales. Against CVS Pharmacy's roughly $142 billion of revenue, the last price a buyer paid for a US drugstore chain implies about $23 billion of enterprise value for a business one sixth larger than Walgreens' pharmacy arm.

Neither benchmark flatters the chain. Walgreens lost $8.6 billion in fiscal 2024 while CVS Pharmacy is profitable, so 0.16x sales is a distressed-chain price rather than a fair one. But the point survives the adjustment: the revealed price of US drugstore equity in private hands is low, and a separated CVS Pharmacy will be measured against it until the market decides it is a health-care asset instead.

Upstream, a 9,000-store chain sits inside a three-company supply system. McKesson, Cencora and Cardinal Health are the national wholesalers, and Drug Channels projects their combined US distribution revenue at $933 billion in 2026. Whatever CVS Pharmacy buys, it buys through that funnel. A separation that forces the chain to contract independently for its own drug purchasing changes who signs the paperwork, but it barely moves three companies with hundreds of billions of revenue each.

Downstream, the swing factor is a contract that does not exist yet. Today Caremark steers Aetna and employer members toward CVS Pharmacy, and that captive channel is part of how a PBM earns its spread. After the split, Caremark must sign the chain at arm's length, and CVS Pharmacy is free to put that business out to bid.

The balance sheet is the binding constraint, not the corporate structure. CVS carried $75.3 billion of debt against $11.7 billion of cash at Sept. 30, 2026 — net debt of $63.6 billion, or 4.85x trailing EBITDA against a peer group running 0.9x to 2.3x. Splitting into two investment-grade companies means the chain absorbs a smaller share of that debt and the health half keeps the rest, which is why the payer-plus-PBM half cannot simply re-rate to Cigna's 2.0x.

Here is what is established and what is not. Established: CVS will separate into two public companies in the first half of 2028, the chain is roughly a third of revenue, the tax-free structure leaves shareholders owning both halves, and today's $180.5 billion enterprise value already exceeds the peer-implied sum of the parts on median benchmarks. Inference: the chain will be valued closer to a health-care asset than to the 0.16x sales private equity paid for Walgreens, because it is bigger, profitable and still attached to 9,000 stores. Speculation: that some strategic or financial buyer will pay up for it — private markets have spent two years taking chains apart, not paying up for them.

So the investable conclusion is uncomfortable for the sum-of-the-parts narrative: makes the pharmacy half, not the PBM, the swing factor in the stock through 2028. Own the operating momentum — a 10.1% trailing free cash flow yield, adjusted EPS guidance of at least $8.20, and at least $15.5 billion of operating cash flow — rather than a discount that the peer multiples say does not exist.